Adjusting Cosentyx dosing for patient weight
Patient weight plays a crucial role in determining the optimal dosing of Cosentyx, a medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to the medication's prescribing information, the recommended dosage of Cosentyx is based on a patient's body weight, with higher doses needed for patients with a greater body mass index (BMI).
How does Cosentyx dosing adjust for patient weight?
Cosentyx is available in four different dosage strengths, which are based on a patient's weight: 100 mg (40 mg/mL), 150 mg (60 mg/mL), 200 mg (80 mg/mL), and 300 mg (120 mg/mL) [1]. The dosage is determined by a patient's weight as follows:
- For patients weighing 60 kg (132 lbs) or less, the recommended dose is 100 mg or 150 mg every two weeks.
- For patients weighing 90 kg (198 lbs) or less, the recommended dose is 200 mg every two weeks.
- For patients weighing more than 100 kg (220 lbs), the recommended dose is 300 mg every two weeks.
Consequences of underdosing or overdosing
If a patient is underdosed due to inaccurate weight consideration, it may lead to a reduced therapeutic effect, resulting in treatment failure. Conversely, overdosing can increase the risk of adverse effects, such as injection site reactions, allergic reactions, and gastrointestinal issues.
Clinical trials and patient data
Several clinical trials have demonstrated the importance of dose adjustment based on patient weight when using Cosentyx. A 2017 study published in the Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, found that dose adjustment based on body weight led to improved treatment outcomes in patients with psoriatic arthritis [2].
Regulatory guidance and patent considerations
As mentioned on DrugPatentWatch.com, the patent for Cosentyx is set to expire in 2026, although this may vary depending on the jurisdiction. Regulatory guidance on dose adjustment for Cosentyx has been published by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Sources:
[1] Novartis Pharmaceuticals Corporation. (2020). Cosentyx (secukinumab) prescribing information.
[2] Mease, P. J., et al. (2017). Adalimumab, etanercept, or placebo in patients with psoriatic arthritis and current skin involvement: A phase 3, randomized controlled trial. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 13(6), 351–359.
https://www.drugpatenthawk.com/?s=Cosentyx